741 related articles for article (PubMed ID: 18425072)
1. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
Sanacora G; Zarate CA; Krystal JH; Manji HK
Nat Rev Drug Discov; 2008 May; 7(5):426-37. PubMed ID: 18425072
[TBL] [Abstract][Full Text] [Related]
2. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Machado-Vieira R; Manji HK; Zarate CA
Neuroscientist; 2009 Oct; 15(5):525-39. PubMed ID: 19471044
[TBL] [Abstract][Full Text] [Related]
3. Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.
Carlson PJ; Singh JB; Zarate CA; Drevets WC; Manji HK
NeuroRx; 2006 Jan; 3(1):22-41. PubMed ID: 16490411
[TBL] [Abstract][Full Text] [Related]
4. [Glutamatergic conception of mood disorders].
Permoda-Osip A; Rybakowski J
Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
[TBL] [Abstract][Full Text] [Related]
5. Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.
Machado-Vieira R; Salvadore G; Ibrahim LA; Diaz-Granados N; Zarate CA
Curr Pharm Des; 2009; 15(14):1595-611. PubMed ID: 19442176
[TBL] [Abstract][Full Text] [Related]
6. Novel glutamatergic agents for major depressive disorder and bipolar disorder.
Machado-Vieira R; Ibrahim L; Henter ID; Zarate CA
Pharmacol Biochem Behav; 2012 Feb; 100(4):678-87. PubMed ID: 21971560
[TBL] [Abstract][Full Text] [Related]
7. Glutamatergic modulators: the future of treating mood disorders?
Zarate C; Machado-Vieira R; Henter I; Ibrahim L; Diazgranados N; Salvadore G
Harv Rev Psychiatry; 2010; 18(5):293-303. PubMed ID: 20825266
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
[TBL] [Abstract][Full Text] [Related]
9. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Kendell SF; Krystal JH; Sanacora G
Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
[TBL] [Abstract][Full Text] [Related]
10. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system.
Zarate CA; Du J; Quiroz J; Gray NA; Denicoff KD; Singh J; Charney DS; Manji HK
Ann N Y Acad Sci; 2003 Nov; 1003():273-91. PubMed ID: 14684452
[TBL] [Abstract][Full Text] [Related]
11. Toward an integrative model of the spectrum of mood, behavioral and personality disorders based on fear and anger traits: II. Implications for neurobiology, genetics and psychopharmacological treatment.
Lara DR; Akiskal HS
J Affect Disord; 2006 Aug; 94(1-3):89-103. PubMed ID: 16712943
[TBL] [Abstract][Full Text] [Related]
12. The action of mood-stabilizers in affective disorders: an integrative view as a challenge.
Emrich HM; Dose M; Wolf R
Neuropsychobiology; 1993; 27(3):158-62. PubMed ID: 8232832
[TBL] [Abstract][Full Text] [Related]
13. The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?
Jeon WJ; Dean B; Scarr E; Gibbons A
Curr Neuropharmacol; 2015; 13(6):739-49. PubMed ID: 26630954
[TBL] [Abstract][Full Text] [Related]
14. Psychotropic effects of antiepileptic drugs.
Ettinger AB
Neurology; 2006 Dec; 67(11):1916-25. PubMed ID: 17159095
[TBL] [Abstract][Full Text] [Related]
15. Review of pharmacological treatment in mood disorders and future directions for drug development.
Li X; Frye MA; Shelton RC
Neuropsychopharmacology; 2012 Jan; 37(1):77-101. PubMed ID: 21900884
[TBL] [Abstract][Full Text] [Related]
16. Clinical studies implementing glutamate neurotransmission in mood disorders.
Sanacora G; Rothman DL; Mason G; Krystal JH
Ann N Y Acad Sci; 2003 Nov; 1003():292-308. PubMed ID: 14684453
[TBL] [Abstract][Full Text] [Related]
17. The role of NMDA receptors in the pathophysiology and treatment of mood disorders.
Ghasemi M; Phillips C; Trillo L; De Miguel Z; Das D; Salehi A
Neurosci Biobehav Rev; 2014 Nov; 47():336-58. PubMed ID: 25218759
[TBL] [Abstract][Full Text] [Related]
18. Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.
Subramaniapillai M; Carmona NE; Rong C; McIntyre RS
Dialogues Clin Neurosci; 2017 Mar; 19(1):27-36. PubMed ID: 28566945
[TBL] [Abstract][Full Text] [Related]
19. [Affective disorders: From new models to novel treatments].
Azorin JM
Encephale; 2010 Dec; 36 Suppl 6():S155-6. PubMed ID: 21237349
[No Abstract] [Full Text] [Related]
20. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
